[1] 韩迎.生物技术药物的优势与前景展望[J].中国医院药学杂志,2013,33(13):1083-1085.
[2] KESIK-BRODACKA M.Progress in biopharmaceutical development[J].Biotechnol Appl Biochem,2018,65(3):306-322.
[3] 刘昌孝.我国药物代谢动力学研究的发展及其对创新药物研发的重要作用[J].中国药理学与毒理学杂志,2015,29(5):686-687.
[4] 张振清.我国药物代谢与药代动力学学科发展与展望[J].中国药理学与毒理学杂志,2015,29(5):752-754.
[5] PARR M K,MONTACIR O,MONTACIR H.Physicochemical characterization of biopharmaceuticals[J].J Pharm Biomed Anal,2016,130:366-389.
[6] 斯琴朝克图,黄玲利,袁宗辉.放射性同位素标记药物在药物代谢与处置研究中的应用[J].中国新药杂志,2016,25(13):1475-1484.
[7] 林立红,余洋,李晓磊,等.放射性同位素示踪法研究2-氟-6-三氟甲基吡啶在大鼠体内的吸收、分布和排泄[J].中国药理学与毒理学杂志,2017,31(6):670-674.
[8] 赵小亮,刘曦,杨忆,等.利用活体成像技术研究海茸β-1,3/1,6-葡聚糖在小鼠体内的分布[J].高等学校化学学报,2017,38(8):1368-1374.
[9] MU LL,LI SW,ZHOU R,et al. The application of immunoassay in bioanalysis[J].中国药学(英文版),2015,24(4):205-216.
[10] LIU C C,FANG G Z,DENG Q L,et al. Determination of metolcarb in food by capillary electrophoresis immunoassay with a laser-induced fluorescence detector[J].Electrophoresis,2012,33(9-10):1471-1476.
[11] WANG J,ZHU X H,KOLLI S,et al. Plasma pharmacokinetics and bioavailability of verticillin A following different routes of administration in mice using liquid chromatography tandem mass spectrometry[J].J Pharm Biomed Anal,2017,139:187-192.
[12] FRANZONI S,VEZZELLI A,TURTORO A,et al. Development and validation of a bioanalytical method for quantification of LNA-i-miR-221,a 13-mer oligonucleotide,in rat plasma using LC-MS/MS[J].J Pharm Biomed Anal,2018,150:300-307.
[13] LIAN D S,ZHAO S J.Highly sensitive analysis of nucleic acids using capillary gel electrophoresis with ultraviolet detection based on the combination of matrix field-amplified and head-column field-amplified stacking injection[J].J Chromatogr B,2015,978-979:29-42.
[14] YU R Z,GRUNDY J S,GEARY R S.Clinical pharmacokinetics of second generation antisense oligonucleotides[J].Expert Opin Drug Metab Toxicol,2013,9(2):169-182.
[15] BURKI U,KEANE J,BLAIN A,et al. Development and application of an ultrasensitive hybridization-based ELISA method for the determination of peptide-conjugated phosphorodiamidate morpholino oligonucleotides[J].Nucleic Acid Ther,2015,25(5):275-284.
[16] THWALA L N,PRÉAT V,CSABA N S.Emerging delivery platforms for mucosal administration of biopharmaceuticals:A critical update on nasal,pulmonary and oral routes[J].Expert Opin Drug Deliv,2017,14(1):23-36.
[17] WALLIS L,KLEYNHANS E,TOIT T,et al. Novel non-invasive protein and peptide drug delivery approaches[J].PPL,2014,21(11):1087-1101.
[18] UENO H,MIZUTA M,SHⅡYA T,et al. Exploratory trial of intranasal administration of glucagon-like peptide-1 in japanese patients with type 2 diabetes:figure 1[J].Dia Care,2014,37(7):2024-2027.
[19] RICHTER W F,JACOBSEN B.Subcutaneous absorption of biotherapeutics:knowns and unknowns[J].Drug Metab Dispos,2014,42(11):1881-1889.
[20] VUGMEYSTER Y.Pharmacokinetics and toxicology of therapeutic proteins:advances and challenges[J].World J Biol Chem,2012,3(4):73.
[21] ZHAO L,REN T H,WANG D D.Clinical pharmacology considerations in biologics development[J].Acta Pharmacol Sin,2012,33(11):1339-1347.
[22] LENE H S,PETERSEN L C,LAURITZEN B,et al. Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor[J].Thromb Res,2014,133(3):464-471.
[23] XIAO G Q,GAN L S.Receptor-mediated endocytosis and brain delivery of therapeutic biologics[J].Int J Cell Biol,2013,2013:1-14.
[24] DENG R,JIN F,PRABHU S,et al. Monoclonal antibodies:what are the pharmacokinetic and pharmacodynamic considerations for drug development[J].Expert Opin Drug Metab Toxicol,2012,8(2):141-160.
[25] SHI S J.Biologics:an update and challenge of their pharmacokinetics[J].Curr Drug Metab,2014,15(3):271-290.
[26] BAUMANN A.Early development of therapeutic biologicspharmacokinetics[J].Curr Drug Metab,2006,7(1):15-21.
[27] PYZIK M,RATH T,LENCER W I,et al. FcRn:the architect behind the immune and nonimmune functions of IgG and albumin[J].J Immunol,2015,194(10):4595-4603.
[28] WILCOX C R,HOLDER B,JONES C E.Factors affecting the FcRn-mediated transplacental transfer of antibodies and implications for vaccination in pregnancy[J].Front Immunol,2017,8:1294.
[29] ROBBIE G J,CRISTE R,DALL'ACQUA W F,et al. A novel investigational fc-modified humanized monoclonal antibody,motavizumab-YTE,has an extended half-life in healthy adults[J].Antimicrob Agents Chemother,2013,57(12):6147-6153.
[30] EZAN E,BECHER F,FENAILLE F.Assessment of the metabolism of therapeutic proteins and antibodies[J].Expert Opin Drug Metab Toxicol,2014,10(8):1079-1091.
[31] KAPLON H,REICHERT J M.Antibodies to watch in 2018[J].mAbs,2018,10(2):183-203.
[32] KAPLON H,REICHERT J M.Antibodies to watch in 2019[J].mAbs,2019,11(2):219-238.
[33] DOSTALEK M,GARDNER I,GURBAXANI B M,et al. Pharmacokinetics,pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies[J].Clin Pharmacokinet,2013,52(2):83-124.
[34] KAMATH A V.Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies[J].Drug Discov Today Technol,2016,21-22:75-83.
[35] LIN J.Pharmacokinetics of biotech drugs:peptides,proteins and monoclonal antibodies[J].Curr Drug Metab,2009,10(7):661-691.
[36] MOULD D R,GREEN B.Pharmacokinetics and pharmacodynamics of monoclonal antibodies[J].BioDrugs,2010,24(1):23-39.